Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Growth differentiation factor 9 (GDF9)
- Target
- GDF9
- Molecular classification
- Growth factor, Member of the transforming growth factor-beta (TGF-β) superfamily, Secreted protein ligand
01
Overview
Growth differentiation factor 9 (GDF9) is a secreted protein member of the transforming growth factor-beta (TGF-β) superfamily, predominantly expressed in oocytes. GDF9 is essential for ovarian folliculogenesis, functioning as a key paracrine regulator of granulosa, cumulus, and theca cell proliferation and differentiation during early and late stages of follicle development[1][3][5]. GDF9 activates SMAD2/3 signaling via BMPRII and ALK5 receptors, influencing gene expression critical to oocyte maturation, cumulus cell expansion, and ovulation. Genetic inactivation or deficiency of GDF9 leads to blocked follicular development and female infertility in animal models and is associated with reproductive disorders in humans. Although no drugs currently target GDF9 directly, its function and signaling are being explored as therapeutic and biomarker opportunities in infertility and reproductive health[1][3][7].
- Other names
- Growth/differentiation factor 9GDF-9POF14growth/differentiation factor 9GDF9
02
Mechanism of action
Ligand binds to bone morphogenetic protein receptor 2 (BMPRII) and transforming growth factor-beta receptor type 1 (ALK5), activating SMAD2/3 signaling pathways to regulate gene expression in ovarian follicular somatic cells[1][3]
03
Biological functions
Ovarian folliculogenesisOocyte maturationRegulation of granulosa and cumulus cell proliferation and differentiationParacrine signaling between oocyte and somatic follicular cellsRegulation of steroidogenesisInhibition of granulosa cell apoptosisPromotion of cumulus cell expansion
04
Disease associations
Infertility (especially female infertility due to ovarian dysfunction)Polycystic ovary syndrome (PCOS)Premature ovarian failurePotential relevance in dizygotic twinning and reproductive disorders
05
Safety considerations
Altered GDF9 activity may disrupt ovarian function leading to infertility or ovarian dysgenesis; potential pleiotropic effects if systemically modulated. No clinical safety data exist for targeted pharmacologic manipulation.
06
Interacting drugs
No approved drugs directly target GDF9; experimental approaches may include recombinant growth factors or modulators in infertility and assisted reproduction contexts[3]
07
Biomarkers
GDF9 levels and genetic variants can serve as biomarkers for oocyte quality, ovarian reserve, or infertility susceptibility, particularly in assisted reproduction settings[7]
Beyond the preview
Go deeper on Growth differentiation factor 9 (GDF9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Growth differentiation factor 9 (GDF9).